Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Cumulative Benefit With Evolocumab in Patients With No Prior Myocardial Infarction or Stroke in the VESALIUS-CV StudyJACC, 2026
- The ABCs of cardiovascular disease prevention: communicating what we know in 2026American Journal of Preventive Cardiology, 2026
- 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of DyslipidemiaJACC, 2026
- Evolocumab in Patients without a Previous Myocardial Infarction or StrokeNew England Journal of Medicine, 2026
- Impact of LDL-Cholesterol When the Coronary Artery Calcium Score Is 0JACC, 2025
- Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a)American Heart Journal, 2025
- Time Course of LDL Cholesterol Exposure and Cardiovascular Disease Event RiskJACC, 2020
- Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular DiseaseJAMA Cardiology, 2019
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood CholesterolJACC, 2019
- Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal EventsJACC, 2019